← All trials
NCT03630081
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 25, 2018
- Primary completion
- Nov 25, 2019
- Completion date
- Nov 25, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 1004
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- WockhardtLead sponsor
- WockhardtStudy director
- Medpace, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.